Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis Press release
Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility Press release
Galderma Receives FDA Approval for AKLIEF® (trifarotene) Cream, 0.005%, the First New Retinoid Molecule for the Treatment of Acne in Over 20 Years Press release
Galderma to become the world’s largest independent global dermatology company after completion of CHF 10.2 billion carve-out of Nestlé Skin Health Press release
Nestlé enters into exclusive negotiations to sell Nestlé Skin Health to a consortium led by EQT and ADIA Press release
Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines Press release
Galderma marks Rosacea Awareness Month with new insights into why some patients are self-treating and launches social media campaign to reinforce hidden impact of the disease Press release
Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting Late-Breaking Session Press release